T9G — Vidac Pharma Holding Cashflow Statement
0.000.00%
- €26.73m
- €27.36m
Annual cashflow statement for Vidac Pharma Holding, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 5 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -0.407 | -0.643 | -1.27 | -1.39 |
Depreciation | ||||
Non-Cash Items | 0 | 0.249 | 0.376 | 0.724 |
Equity in Net Earnings/Losses | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.016 | -0.075 | 0.216 | -0.08 |
Change in Accounts Receivable | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Cash from Operating Activities | -0.391 | -0.468 | -0.682 | -0.742 |
Capital Expenditures | 0 | — | — | — |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | 0 | 0.008 | 0 | 0 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | 0 | 0.008 | 0 | 0 |
Financing Cash Flow Items | 0.028 | — | — | — |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.282 | 0.401 | 0.715 | 1.15 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -0.123 | -0.089 | 0.026 | 0.38 |